← All trials
NCT05788679
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 22, 2022
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- Mar 29, 2023
- Last posted
- Dec 5, 2023
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Karolinska InstituteLead sponsor
- Karolinska InstituteOverall official - principal investigator
- Karolinska InstituteReponsible party - principal investigator
- Karolinska InstituteSponsor investigator
- Nordic MDS GroupCollaborator
- Karolinska InstituteOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.